Business Context and Reporting Period
Company: Arrowhead Research Corporation (formerly InterActive Group, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2008
Business Model: Arrowhead is a nanotechnology holding company that builds and manages subsidiaries to commercialize technologies in healthcare, electronics, and clean energy. The company aims to monetize these subsidiaries through sales, IPOs, or consolidation of earnings.
Key Subsidiaries:
- Calando Pharmaceuticals (67.8% owned): Clinical-stage RNAi therapeutics and drug delivery systems.
- Unidym, Inc. (53.8% owned): Carbon nanotube products for the electronics industry.
- Tego Biosciences (100% owned): Fullerene-based therapeutic and diagnostic applications.
- Agonn Systems (100% owned): Nanotechnology-based energy storage devices.
Minority Investments: Nanotope, Inc. (22%) and Leonardo Biosystems, Inc. (6%).
Key Financial Metrics
| Metric | Fiscal 2008 | Fiscal 2007 |
|---|---|---|
| Revenue | $1,303,201 | $1,208,022 |
| Net Loss | $(27,089,030) | $(29,931,118) |
| Operating Loss | $(35,002,581) | $(37,091,978) |
| Cash and Cash Equivalents (End of Period) | $10,093,585 | $24,120,097 |
| Working Capital | $8,176,818 | $22,409,053 |
| Total Assets | $17,255,442 | $29,852,952 |
| Stockholders' Equity | $12,302,609 | $26,303,968 |
Revenue Composition (2008): $570,000 from grants, $85,000 from license fees, and $648,000 from carbon nanotube sales.
Debt and Liquidity: The company has no significant long-term debt on the consolidated balance sheet as of September 30, 2008, but subsidiaries have incurred obligations. Calando has $2.7 million in unsecured convertible promissory notes (subsequent to period end, $1.1 million received). Unidym has a capital lease obligation of approximately $1.54 million.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $2.8 million compared to 2007. This improvement was primarily driven by the absence of a $9.6 million non-recurring expense in 2007 related to purchased in-process research and development (IPR&D) from the Carbon Nanotechnologies, Inc. (CNI) merger.
- Cash Position: Cash and cash equivalents declined significantly by approximately $14 million (from $24.1 million to $10.1 million) due to high operating cash burn and investment activities.
- Operating Expenses: Total operating expenses decreased from $38.3 million in 2007 to $36.3 million in 2008. Research and Development (R&D) expenses dropped significantly from $21.0 million to $12.1 million, largely due to the one-time IPR&D charge in the prior year and reduced outside lab costs at Calando.
- Discontinued Operations: The company sold its majority-owned subsidiary, Aonex Technologies, Inc., in May 2008, resulting in a gain on sale of $306,344. Losses from Aonex are now reported as discontinued operations.
Guidance, Outlook, and Risks
Management Commentary & Strategy:
- Cash Conservation: Management has adopted a strict cash conservation strategy. If additional capital is not secured by mid-second quarter of 2009, the company plans to make deeper cuts in development efforts at Calando and Unidym and reduce corporate expenses to fund limited operations through fiscal 2010.
- Capital Raising: The Board is actively pursuing out-licensing of technology, sale of subsidiaries, funded partnerships, and sale of securities to raise capital.
- Subsidiary Specifics:
- Calando: Completed Phase I trials for IT-101 and initiated Phase I for CALAA-01. Cash consumption ranges from $2.2M to $2.6M per quarter.
- Unidym: Cash burn increased to $4.2 million in Q4 2008. The company has eliminated executive positions and placed half of its Houston staff on unpaid leave. It is consolidating facilities and exploring outsourcing of production.
Risks and Contingencies:
- Going Concern: The filing explicitly states that the company's ability to continue as a going concern is dependent on obtaining additional financing. Without it, operations must be scaled back significantly.
- Intellectual Property (IP) Risk: Unidym's critical IP is licensed from Rice University. If Unidym fails to meet financial covenants or becomes insolvent, the license could terminate, severely impacting the subsidiary's value. Additionally, a recent $2 million investment from TEL Ventures includes a put option that could force Unidym to repurchase shares or lose collateral IP if cash requirements are not met by June 2009.
- Market Conditions: The financial crisis has limited access to capital and made an IPO for Unidym unfeasible in the near term.
- Stock Listing: The company's stock price fell below $1.00 in October 2008, violating NASDAQ listing requirements. While enforcement was temporarily suspended, delisting remains a risk if the price does not recover.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance and the status of the $2.7 million Calando note and $2 million Unidym financing mentioned as subsequent events.
- Unidym IP Covenants: Confirm Unidym's compliance with Rice University financial covenants and the status of the TEL Ventures put option obligations due in mid-2009.
- Calando Clinical Progress: Monitor the results of the CALAA-01 Phase I trial and the initiation of the IT-101 Phase II trial for ovarian cancer.
- Cost Cutting Execution: Assess whether the planned personnel reductions and facility consolidations at Unidym and Calando are being executed to lower the cash burn rate.
- NASDAQ Compliance: Track the stock price to ensure it remains above the $1.00 threshold required for continued NASDAQ listing once the temporary suspension is lifted.